Home › Compare › TSCHY vs ABBV
TSCHY yields 1081.08% · ABBV yields 3.06%● Live data
📍 TSCHY pulled ahead of the other in Year 1
Combined, TSCHY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TSCHY + ABBV for your $10,000?
Trustco Group Holdings Limited, together with its subsidiaries, provides banking, financial, and insurance related products and services. The company operates through three segments: Insurance and its Investments, Banking and Finance, and Resources. The Insurance and its Investments segment provides short- and long-term insurance products and services to individuals, and small and medium enterprises. This segment also invests primarily in mixed use land development, as well as offers construction and management services; and engages in the provision of education services. The Banking and Finance segment provides commercial banking and micro-finance to individuals and businesses; financial assistance services for educational and training purposes; and long-term property advances. The Resources segment primarily conducts mining operations with focus on diamond industry. It has operations in Namibia, South Africa, Mauritius, and Sierra Leone. Trustco Group Holdings Limited was founded in 1992 and is headquartered in Windhoek, Namibia.
Full TSCHY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.